

Jorge Cortes

List of Publications by Citations

Source: <https://exaly.com/author-pdf/11531546/jorge-cortes-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

393 papers	43,164 citations	110 h-index	199 g-index
399 ext. papers	47,493 ext. citations	5.8 avg, IF	6.92 L-index

#	Paper	IF	Citations
393	Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. <i>New England Journal of Medicine</i> , 2006 , 354, 2531-41	59.2	1414
392	Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. <i>New England Journal of Medicine</i> , 2010 , 362, 2260-70	59.2	1197
391	Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. <i>New England Journal of Medicine</i> , 2006 , 354, 2542-51	59.2	1133
390	Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. <i>Journal of Clinical Oncology</i> , 2009 , 27, 6041-51	2.2	1019
389	Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. <i>Blood</i> , 2006 , 108, 1809-20	2.2	998
388	Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. <i>Blood</i> , 2006 , 108, 28-37	2.2	977
387	Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2005 , 23, 4079-88	2.2	811
386	Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2Pdeoxycytidine (decitabine) in hematopoietic malignancies. <i>Blood</i> , 2004 , 103, 1635-40	2.2	694
385	Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2000 , 18, 547-61	2.2	616
384	Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. <i>Blood</i> , 2007 , 109, 52-7	2.2	577
383	Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. <i>Blood</i> , 2008 , 112, 975-80	2.2	568
382	Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. <i>Journal of Clinical Investigation</i> , 2011 , 121, 396-409	15.9	555
381	Rituximab dose-escalation trial in chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2001 , 19, 2165-70	2.2	527
380	Molecular biology of bcr-abl1-positive chronic myeloid leukemia. <i>Blood</i> , 2009 , 113, 1619-30	2.2	482
379	Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. <i>Cancer</i> , 2004 , 101, 2788-801	6.4	461
378	Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. <i>Blood</i> , 2004 , 103, 4396-407	2.2	458
377	Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2005 , 23, 4070-8	2.2	447

376	Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. <i>Cancer</i> , 2006 , 106, 1569-80	6.4	441
375	Phase 1/2 study of the combination of 5-aza-2Pdeoxycytidine with valproic acid in patients with leukemia. <i>Blood</i> , 2006 , 108, 3271-9	2.2	441
374	miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. <i>Cell</i> , 2010 , 140, 652-65	56.2	427
373	Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. <i>Cancer Discovery</i> , 2014 , 4, 362-75	24.4	420
372	Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. <i>Blood</i> , 2008 , 111, 1060-6	2.2	397
371	Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. <i>Cancer</i> , 2008 , 113, 1351-61	6.4	386
370	Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. <i>Blood</i> , 2007 , 109, 3207-13	2.2	354
369	Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. <i>Lancet Oncology, The</i> , 2012 , 13, 403-11	21.7	350
368	Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. <i>Blood</i> , 2007 , 110, 2302-8	2.2	347
367	High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. <i>Blood</i> , 2004 , 103, 2873-8	2.2	344
366	MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. <i>Blood</i> , 2007 , 109, 500-2	2.2	323
365	Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5418-24	2.2	317
364	Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). <i>Blood</i> , 2014 , 123, 494-500	2.2	309
363	Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. <i>Lancet Oncology, The</i> , 2017 , 18, 1061-1075	21.7	305
362	Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3908-14	2.2	301
361	Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3880-9	2.2	299
360	Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2001 , 19, 1414-20	2.2	299
359	Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. <i>Blood</i> , 2013 , 121, 4655-62	2.2	296

358	Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. <i>Blood</i> , 2011 , 117, 1141-5	2.2	296
357	Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 184-98	9.7	295
356	A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. <i>Clinical Cancer Research</i> , 2006 , 12, 4628-35	12.9	288
355	International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). <i>Blood</i> , 2006 , 108, 1497-503	2.2	287
354	Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. <i>Blood</i> , 2003 , 102, 2379-86	2.2	281
353	Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. <i>Blood</i> , 2003 , 101, 473-5	2.2	273
352	FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. <i>Journal of Clinical Investigation</i> , 2007 , 117, 2408-21	15.9	270
351	Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. <i>Blood</i> , 2007 , 109, 4679-85	2.2	264
350	Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3948-56	2.2	259
349	The effects of imatinib on pregnancy outcome. <i>Blood</i> , 2008 , 111, 5505-8	2.2	256
348	First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. <i>Blood</i> , 2010 , 116, 2070-7	2.2	255
347	Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. <i>Blood</i> , 2008 , 111, 1834-9	2.2	255
346	Discontinuation of imatinib therapy after achieving a molecular response. <i>Blood</i> , 2004 , 104, 2204-5	2.2	253
345	Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. <i>Blood</i> , 2002 , 99, 3547-53	2.2	251
344	Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. <i>Blood</i> , 2012 , 119, 1981-7	2.2	249
343	Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4204-10	2.2	248
342	Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. <i>Blood</i> , 2007 , 110, 4005-11	2.2	247
341	Flying under the radar: the new wave of BCR-ABL inhibitors. <i>Nature Reviews Drug Discovery</i> , 2007 , 6, 834-48	16.1	246

340	Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. <i>Clinical Cancer Research</i> , 2005 , 11, 3425-32	12.9	237
339	Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. <i>Nature Reviews Drug Discovery</i> , 2011 , 10, 127-40	64.1	229
338	Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. <i>American Journal of Hematology</i> , 2018 , 93, 401-407	7.1	229
337	Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. <i>Cancer</i> , 2013 , 119, 2728-36	6.4	225
336	Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. <i>Blood</i> , 2008 , 112, 981-9	2.2	222
335	Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. <i>Blood</i> , 2003 , 101, 3413-5	2.2	220
334	Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 1999 , 17, 2461-70	2.2	213
333	Congestive heart failure is a rare event in patients receiving imatinib therapy. <i>Blood</i> , 2007 , 110, 1233-7	2.2	205
332	Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. <i>Blood</i> , 2004 , 104, 1624-30	2.2	202
331	Results of decitabine (5-aza-2'-deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. <i>Cancer</i> , 2003 , 98, 522-8	6.4	200
330	Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. <i>Cancer</i> , 2010 , 116, 3830-4	6.4	195
329	Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. <i>Blood</i> , 2005 , 105, 940-7	2.2	193
328	Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. <i>Blood</i> , 2017 , 129, 572-581	2.2	191
327	AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. <i>Clinical Cancer Research</i> , 2005 , 11, 4941-7	12.9	189
326	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. <i>Lancet Oncology</i> , 2015 , 16, 1547-1555	21.7	188
325	Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. <i>Cancer</i> , 2012 , 118, 3123-7	6.4	187
324	New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. <i>Annals of Internal Medicine</i> , 2006 , 145, 913-23	8	187
323	Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2003 , 98, 2657-63	6.4	186

322	Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. <i>Blood</i> , 2010 , 115, 1131-6	2.2	185
321	Pregnancy among patients with chronic myeloid leukemia treated with imatinib. <i>Journal of Clinical Oncology</i> , 2006 , 24, 1204-8	2.2	183
320	Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. <i>Blood</i> , 2006 , 108, 1835-40	2.2	181
319	Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. <i>Blood</i> , 2008 , 111, 1039-43	2.2	175
318	PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. <i>Journal of Clinical Investigation</i> , 2013 , 123, 4144-57	15.9	170
317	Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. <i>Blood</i> , 2012 , 120, 4840-5	2.2	169
316	Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). <i>Cancer</i> , 2009 , 115, 4136-47	6.4	168
315	Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. <i>Journal of Clinical Oncology</i> , 2003 , 21, 1167-73	2.2	168
314	Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. <i>Blood</i> , 2003 , 102, 83-6	2.2	164
313	Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. <i>Cancer</i> , 2007 , 109, 1133-7	6.4	158
312	Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α . <i>Blood</i> , 2013 , 122, 893-901	2.2	156
311	Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. <i>Cancer</i> , 1999 , 86, 1216-30	6.4	153
310	Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. <i>Blood</i> , 2009 , 114, 261-3	2.2	151
309	Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. <i>Blood</i> , 2009 , 113, 6330-7	2.2	149
308	Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. <i>Cancer</i> , 1999 , 86, 2632-41	6.4	143
307	Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. <i>Blood</i> , 2009 , 113, 6322-9	2.2	137
306	Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. <i>Blood</i> , 2007 , 109, 497-9	2.2	137
305	Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. <i>Clinical Cancer Research</i> , 2008 , 14, 3906-15	12.9	136

304	Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2015 , 100, 653-61	6.6	135
303	Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. <i>Blood</i> , 2009 , 113, 2154-60 ^{2,2}		135
302	Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4760-6	2.2	133
301	Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. <i>Blood</i> , 2006 , 108, 45-51	2.2	132
300	Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. <i>Blood</i> , 2006 , 108, 2811-3	2.2	130
299	Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. <i>Blood</i> , 2009 , 113, 6315-21	2.2	129
298	Rituximab in relapsed or refractory hairy cell leukemia. <i>Blood</i> , 2003 , 102, 3906-11	2.2	127
297	Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. <i>Journal of Clinical Oncology</i> , 1999 , 17, 284-92	2.2	126
296	Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. <i>Cancer</i> , 2002 , 94, 1492-9	6.4	123
295	Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. <i>Blood</i> , 2009 , 114, 2232-5	2.2	122
294	Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2000 , 36, 263-73	1.9	121
293	Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. <i>Journal of Hematology and Oncology</i> , 2019 , 12, 1	22.4	119
292	The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. <i>Blood</i> , 2011 , 118, 4541-6; quiz 4759	2.2	115
291	Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. <i>Cancer</i> , 2007 , 109, 899-906	6.4	115
290	Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2015 , 90, 276-81 ¹		114
289	Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. <i>Blood</i> , 2007 , 110, 2991-5	2.2	114
288	Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. <i>Cancer</i> , 2003 , 98, 1905-11	6.4	114
287	Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. <i>Blood</i> , 2008 , 111, 1774-80	2.2	112

286	Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. <i>Blood</i> , 2008 , 112, 53-5	2.2	111
285	Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. <i>Blood</i> , 2013 , 121, 4867-74	2.2	110
284	Imatinib and beyond--exploring the full potential of targeted therapy for CML. <i>Nature Reviews Clinical Oncology</i> , 2009 , 6, 535-43	19.4	110
283	Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. <i>Cancer</i> , 2007 , 109, 248-55	6.4	108
282	The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. <i>Blood</i> , 2009 , 114, 4361-8	2.2	107
281	Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. <i>Cancer</i> , 2007 , 109, 713-7	6.4	106
280	Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4088-95	2.2	105
279	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. <i>Lancet Haematology</i> , 2018 , 5, e618-e627	14.6	105
278	Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. <i>Blood</i> , 2009 , 114, 2037-43	2.2	103
277	Outcome of adults with acute lymphocytic leukemia after second salvage therapy. <i>Cancer</i> , 2008 , 113, 3186-91	6.4	103
276	Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. <i>Blood</i> , 2017 , 130, 1514-1522	2.2	102
275	Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. <i>Cancer</i> , 2009 , 115, 5382-93	6.4	102
274	Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 897-901	2	101
273	Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 323-34 ²		100
272	Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. <i>Blood</i> , 2012 , 120, 2573-80	2.2	100
271	Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. <i>Cancer</i> , 2015 , 121, 556-61	6.4	99
270	Nilotinib-associated vascular events. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012 , 12, 337-40	2	99
269	Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. <i>Current Medical Research and Opinion</i> , 2010 , 26, 61-9	2.5	99

268	Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. <i>Cancer</i> , 2009 , 115, 2482-90	6.4	98
267	Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. <i>Cancer</i> , 2009 , 115, 551-60	6.4	97
266	The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. <i>Cancer</i> , 2007 , 110, 1509-19	6.4	97
265	Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. <i>Cancer</i> , 2010 , 116, 3852-61	6.4	96
264	Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. <i>Cancer</i> , 2003 , 97, 2760-6	6.4	96
263	Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or transformation of chronic lymphocytic leukemia. <i>Cancer</i> , 2003 , 97, 1711-22	6.4	94
262	Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. <i>Science Translational Medicine</i> , 2016 , 8, 355ra117	17.5	93
261	Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, 230-234	13.4	92
260	Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. <i>Blood</i> , 2005 , 105, 2281-6	2.2	92
259	Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?. <i>Cancer</i> , 2008 , 112, 837-45	6.4	91
258	Secondary mutations as mediators of resistance to targeted therapy in leukemia. <i>Blood</i> , 2015 , 125, 3236-45	2.5	90
257	Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. <i>Cancer</i> , 2006 , 106, 1099-109	6.4	89
256	How I treat newly diagnosed chronic phase CML. <i>Blood</i> , 2012 , 120, 1390-7	2.2	88
255	Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. <i>Blood</i> , 2009 , 114, 5271-8	2.2	87
254	Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. <i>Blood</i> , 2016 , 127, 1269-75	2.2	87
253	Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. <i>Cancer</i> , 2009 , 115, 3709-18	6.4	86
252	Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. <i>Leukemia Research</i> , 2010 , 34, 752-6	2.7	85
251	Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. <i>Cancer</i> , 2009 , 115, 5746-51	6.4	83

250	Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. <i>Clinical Cancer Research</i> , 2008 , 14, 4392-9	12.9	83
249	Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. <i>Leukemia and Lymphoma</i> , 2013 , 54, 1411-7	1.9	79
248	Important therapeutic targets in chronic myelogenous leukemia. <i>Clinical Cancer Research</i> , 2007 , 13, 1089-97	2.7	78
247	Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. <i>Blood</i> , 2006 , 108, 1421-3	2.2	77
246	Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. <i>Cancer</i> , 2003 , 98, 2636-42	6.4	77
245	Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial. <i>Haematologica</i> , 2012 , 97, 731-8	6.6	76
244	Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. <i>Cancer</i> , 2007 , 109, 1556-60	6.4	75
243	Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. <i>Lancet Haematology</i> , 2017 , 4, e165-e175	14.6	74
242	Management of imatinib-resistant patients with chronic myeloid leukemia. <i>Therapeutic Advances in Hematology</i> , 2013 , 4, 103-17	5.7	74
241	Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. <i>Cancer</i> , 2008 , 113, 1933-52	6.4	74
240	Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. <i>Cancer</i> , 2003 , 98, 1105-13	6.4	74
239	Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. <i>Blood</i> , 2011 , 118, 4353-8	2.2	73
238	Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. <i>Cancer</i> , 2006 , 106, 120-7	6.4	73
237	Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. <i>Journal of Clinical Oncology</i> , 2000 , 18, 3513-21	2.2	73
236	Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. <i>Lancet Haematology</i> , 2015 , 2, e376-83	14.6	71
235	Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2011 , 29, 524-31	2.2	70
234	AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. <i>Cancer</i> , 2005 , 104, 1230-6	6.4	69
233	Frontline treatment of acute myeloid leukemia in adults. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 110, 20-34	7	68

232	Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. <i>Blood</i> , 2008 , 112, 4839-42	2.2	68
231	Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1637-43	2.2	67
230	Clonal evolution in chronic myelogenous leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2004 , 18, 671-84, x	3.1	67
229	Natural history and staging of chronic myelogenous leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2004 , 18, 569-84, viii	3.1	65
228	Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. <i>Journal of Clinical Oncology</i> , 2010 , 28, 285-91	2.2	64
227	Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. <i>Nature Communications</i> , 2019 , 10, 244	17.4	63
226	Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. <i>Haematologica</i> , 2012 , 97, 1029-35	6.6	62
225	Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. <i>Cancer</i> , 2003 , 98, 888-93	6.4	62
224	Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. <i>Lancet Haematology</i> , 2019 , 6, e29-e37	14.6	62
223	Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. <i>Cancer</i> , 2018 , 124, 4044-4055	6.4	62
222	Chronic myelogenous leukemia: a review and update of therapeutic strategies. <i>Cancer</i> , 2003 , 98, 437-57	6.4	61
221	Chronic myeloid leukemia: reminiscences and dreams. <i>Haematologica</i> , 2016 , 101, 541-58	6.6	61
220	Treatment-free remission with first- and second-generation tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2019 , 94, 346-357	7.1	61
219	Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. <i>Cancer</i> , 2007 , 110, 340-4	6.4	57
218	A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. <i>Cancer</i> , 2006 , 106, 337-45	6.4	56
217	Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. <i>American Journal of Hematology</i> , 2018 , 93, 1136-1141	7.1	54
216	Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. <i>Blood</i> , 2011 , 117, 1822-7	2.2	54
215	Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. <i>Blood</i> , 2006 , 107, 480-2	2.2	53

214	Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. <i>Cancer</i> , 2004 , 100, 2592-7	6.4	53
213	Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. <i>American Journal of Hematology</i> , 2018 , 93, 371-374	7.1	53
212	Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. <i>Lancet Haematology</i> , 2015 , 2, e118-28	14.6	52
211	Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. <i>Blood</i> , 2011 , 118, 1622-31	2.2	52
210	Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3659-63	2.2	52
209	Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. <i>Blood</i> , 2011 , 117, 3641-7	2.2	51
208	Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies. <i>Cancer</i> , 2010 , 116, 2290-300	6.4	51
207	Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. <i>Leukemia</i> , 2019 , 33, 1835-1850	10.7	50
206	Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. <i>Cancer</i> , 2009 , 115, 3924-34	6.4	50
205	EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. <i>Blood</i> , 2012 , 119, 4524-6	2.2	49
204	Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications. <i>Cancer</i> , 2011 , 117, 688-97	6.4	49
203	Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous leukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. <i>Clinical Cancer Research</i> , 2004 , 10, 68-75	12.9	49
202	CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2002 , 26, 643-9	2.7	48
201	Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet. <i>HemaSphere</i> , 2018 , 2, e150	0.3	48
200	Biphenotypic acute leukaemia: a case series. <i>British Journal of Haematology</i> , 2007 , 138, 213-6	4.5	47
199	Chronic myelogenous leukaemia with p185(BCR/ABL) expression: characteristics and clinical significance. <i>British Journal of Haematology</i> , 1999 , 107, 581-6	4.5	47
198	Long-term follow-up of lower dose dasatinib (50mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. <i>Cancer</i> , 2020 , 126, 67-75	6.4	47
197	Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors. <i>Cancer</i> , 2011 , 117, 897-906	6.4	46

196	Tyrosine kinase inhibitors: the first decade. <i>Current Hematologic Malignancy Reports</i> , 2010 , 5, 70-80	4.4	46
195	Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. <i>Cancer</i> , 2007 , 110, 1295-302	6.4	46
194	Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment. <i>Mayo Clinic Proceedings</i> , 2005 , 80, 390-402	6.4	46
193	New targeted approaches in chronic myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6316-24	2.2	45
192	Treatment selection after imatinib resistance in chronic myeloid leukemia. <i>Targeted Oncology</i> , 2009 , 4, 3-10	5	44
191	Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3173-8	3.3	44
190	Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations. <i>Cancer</i> , 2008 , 112, 1744-53	6.4	44
189	The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma. <i>Cancer</i> , 2002 , 94, 2738-44	6.4	44
188	HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. <i>Cancer</i> , 2014 , 120, 373-80	6.4	43
187	Central nervous system involvement in adult acute lymphocytic leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2001 , 15, 145-62	3.1	43
186	Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System. <i>American Journal of Hematology</i> , 2015 , 90, E66-72	7.1	42
185	Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. <i>Cancer</i> , 2010 , 116, 2673-81	6.4	42
184	Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1218-1226	4.7	42
183	Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2014 , 89, 282-7	7.1	41
182	Tyrosine kinase inhibitors in acute and chronic leukemias. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 927-38	4	41
181	Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. <i>Cancer</i> , 2011 , 117, 572-80	6.4	41
180	A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. <i>Leukemia and Lymphoma</i> , 2007 , 48, 283-9	1.9	40
179	Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing. <i>Journal of Hematology and Oncology</i> , 2013 , 6, 79	22.4	39

178	The BCR-ABL T315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. <i>Haematologica</i> , 2013 , 98, 1510-6	6.6	39
177	Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. <i>Cancer</i> , 2010 , 116, 2665-72	6.4	39
176	A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2015 , 21, 2704-14	12.9	38
175	Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1392-7	1.9	37
174	Evolution of therapies for chronic myelogenous leukemia. <i>Cancer Journal (Sudbury, Mass)</i> , 2011 , 17, 465-76	2.5	37
173	Advanced-phase chronic myeloid leukemia. <i>Seminars in Hematology</i> , 2003 , 40, 79-86	4	37
172	Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. <i>Cancer</i> , 2019 , 125, 2579-2586	6.4	35
171	Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase. <i>Cancer</i> , 2010 , 116, 1419-30	6.4	35
170	Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. <i>British Journal of Cancer</i> , 2018 , 118, 1425-1433	8.7	35
169	SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2014 , 166, 862-74	4.5	34
168	Chronic myeloid leukemia: mechanisms of resistance and treatment. <i>Hematology/Oncology Clinics of North America</i> , 2011 , 25, 981-95, v	3.1	34
167	Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2010 , 150, 303-12	4.5	34
166	New agents in acute myeloid leukemia and other myeloid disorders. <i>Cancer</i> , 2004 , 100, 441-54	6.4	34
165	Progress in acute myeloid leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 139-51	2	33
164	Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. <i>American Journal of Hematology</i> , 2015 , 90, 193-6	7.1	33
163	Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. <i>Cancer</i> , 2009 , 115, 3935-43	6.4	33
162	Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. <i>Cancer</i> , 2018 , 124, 2740-2747	6.4	32
161	Chronic myeloid leukemia: overview of new agents and comparative analysis. <i>Current Treatment Options in Oncology</i> , 2013 , 14, 127-43	5.4	32

160	Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia. <i>Blood Reviews</i> , 2014 , 28, 179-87	11.1	30
159	A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Cancer</i> , 2011 , 117, 1236-44	6.4	30
158	Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. <i>Clinical Cancer Research</i> , 2005 , 11, 6247-55	12.9	30
157	Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 2509-16	6.1	29
156	Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience. <i>American Journal of Hematology</i> , 2015 , 90, 27-30	7.1	28
155	A multinational study of health state preference values associated with chronic myelogenous leukemia. <i>Value in Health</i> , 2010 , 13, 103-11	3.3	28
154	BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias. <i>Blood</i> , 2008 , 112, 5190-2	2.2	28
153	Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias. <i>Expert Opinion on Investigational Drugs</i> , 2007 , 16, 679-87	5.9	28
152	Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia. <i>Current Molecular Medicine</i> , 2005 , 5, 615-23	2.5	28
151	Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia. <i>Clinical Cancer Research</i> , 2005 , 11, 7817-24	12.9	28
150	Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia/ Polycythemia Vera Myelofibrosis.. <i>Blood</i> , 2009 , 114, 3905-3905	2.2	28
149	Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. <i>Oncotarget</i> , 2015 , 6, 30487-99	3.3	28
148	Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34-positive compartment. <i>Cancer</i> , 2012 , 118, 5283-92	6.4	27
147	Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012 , 12, 207-12	2	26
146	Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012 , 12, 244-51	2	26
145	Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. <i>Cancer</i> , 2006 , 107, 1525-9	6.4	26
144	A Phase 1/2 Study of SKI-606, a Dual Inhibitor of Src and Abl Kinases, in Adult Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphocytic Leukemia (ALL) Relapsed, Refractory or Intolerant of Imatinib.. <i>Blood</i> , 2006 , 108, 168-168	2.2	26
143	A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis. <i>Blood</i> , 2008 , 112, 98-98	2.2	26

142	Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , 2015 , 56, 120-7	1.9	25
141	Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2014 , 23, 943-54	5.9	25
140	A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. <i>Cancer</i> , 2012 , 118, 722-8	6.4	25
139	Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011 , 11, 361-6	2	25
138	Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. <i>American Journal of Hematology</i> , 2017 , 92, 279-285	7.1	24
137	Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1512-6	2.2	24
136	Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the "best" therapy?. <i>Current Oncology Reports</i> , 2010 , 12, 302-13	6.3	24
135	Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review. <i>Core Evidence</i> , 2010 , 4, 207-13	4.9	23
134	Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha. <i>Leukemia and Lymphoma</i> , 2008 , 49, 1399-402	1.9	23
133	New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance. <i>Seminars in Hematology</i> , 2007 , 44, S25-31	4	23
132	Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. <i>American Journal of Hematology</i> , 2019 , 94, 984-991	7.1	22
131	BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors. <i>Acta Haematologica</i> , 2009 , 121, 27-31	2.7	22
130	Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors. <i>Clinical Lymphoma and Myeloma</i> , 2007 , 7 Suppl 3, S105-12		22
129	Advances in the therapy of chronic idiopathic myelofibrosis. <i>Oncologist</i> , 2006 , 11, 929-43	5.7	22
128	Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy. <i>Cancer</i> , 2005 , 104, 777-80	6.4	22
127	Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 71, 1599-607	3.5	21
126	Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. <i>Blood</i> , 2009 , 113, 5058-63	2.2	21
125	Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia. <i>Seminars in Oncology</i> , 2008 , 35, S1-17; quiz S18-20	5.5	21

124	Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases. <i>Future Oncology</i> , 2008 , 4, 611-21	3.6	21
123	Novel tyrosine kinase inhibitors in chronic myelogenous leukemia. <i>Current Opinion in Oncology</i> , 2006 , 18, 578-83	4.2	21
122	Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia. <i>Seminars in Hematology</i> , 2013 , 50, 271-83	4	20
121	Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. <i>American Journal of Hematology</i> , 2015 , 90, 769-73	7.1	20
120	Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. <i>Cancer</i> , 2010 , 116, 3631-7	6.4	20
119	New strategies in chronic myeloid leukemia. <i>International Journal of Hematology</i> , 2006 , 83, 289-93	2.3	20
118	Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1446-54	4.7	19
117	Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013 , 13, 477-84	2	19
116	Current patient management of chronic myeloid leukemia in Latin America: a study by the Latin American Leukemia Net (LALNET). <i>Cancer</i> , 2010 , 116, 4991-5000	6.4	19
115	Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase. <i>Cancer</i> , 2001 , 92, 2501-7	6.4	19
114	A Phase I Evaluation of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis: Clinical Response Is Accompanied by Significant Reduction in JAK2V617F Allele Burden.. <i>Blood</i> , 2009 , 114, 755-755	2.2	19
113	Cardiovascular toxicity of tyrosine kinase inhibitors. <i>Expert Opinion on Drug Safety</i> , 2013 , 12, 687-96	4.1	18
112	The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013 , 13, 302-6	2	18
111	The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Expert Review of Anticancer Therapy</i> , 2015 , 15, 365-73	3.5	17
110	Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16, 152-62	2	17
109	Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases?. <i>Current Hematologic Malignancy Reports</i> , 2011 , 6, 58-66	4.4	17
108	Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Current Hematologic Malignancy Reports</i> , 2011 , 6, 187-94	4.4	17
107	Monitoring molecular response in chronic myeloid leukemia. <i>Cancer</i> , 2011 , 117, 1113-22	6.4	17

106	Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. <i>Cancer</i> , 2011 , 117, 327-35	6.4	17
105	Third-generation tyrosine kinase inhibitors and beyond. <i>Seminars in Hematology</i> , 2010 , 47, 371-80	4	17
104	Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia. <i>Haematologica</i> , 2007 , 92, 170-5	6.6	17
103	INCB018424, an Oral, Selective JAK2 Inhibitor, Shows Significant Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF).. <i>Blood</i> , 2007 , 110, 558-558	2.2	17
102	Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. <i>Haematologica</i> , 2017 , 102, 519-528	6.6	16
101	Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2238-2241	1.9	16
100	Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen. <i>Cancer</i> , 2010 , 116, 4580-9	6.4	16
99	Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib. <i>Future Oncology</i> , 2006 , 2, 655-65	3.6	16
98	Overcoming drug resistance in chronic myeloid leukemia. <i>Current Opinion in Hematology</i> , 2006 , 13, 79-86	3.3	16
97	Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia. <i>Expert Review of Hematology</i> , 2016 , 9, 419-248	2.4	15
96	Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011 , 11, 355-60	2	15
95	Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy. <i>Haematologica</i> , 2011 , 96, 918-21	6.6	15
94	Experimental therapeutics for patients with myeloproliferative neoplasias. <i>Cancer</i> , 2011 , 117, 662-76	6.4	15
93	Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction. <i>Cancer</i> , 2010 , 116, 3152-9	6.4	15
92	Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOPAD) in patients with relapsed/refractory acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2015 , 90, 120-4	7.1	14
91	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia 2016 , 4, 90		14
90	Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017 , 143, 1311-1318	4.9	13
89	BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival. <i>Cancer Investigation</i> , 2015 , 33, 451-8	2.1	13

88	Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014 , 14, 327-334.e8	2	13
87	Chronic myeloid leukemia in adolescents and young adults: patient characteristics, outcomes and review of the literature. <i>Acta Haematologica</i> , 2014 , 132, 298-306	2.7	13
86	The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. <i>American Journal of Hematology</i> , 2020 , 95, 144-150	7.1	13
85	Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes. <i>British Journal of Haematology</i> , 2016 , 173, 114-126	4.5	12
84	Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib. <i>Haematologica</i> , 2014 , 99, 1701-9	6.6	12
83	Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios. <i>Annals of Hematology</i> , 2017 , 96, 1303-1313	3	12
82	Treatment options for chronic myeloid leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 815-28	4	12
81	The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011 , 11, 421-6	2	12
80	Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib. <i>Cancer</i> , 2011 , 117, 5085-93	6.4	12
79	Mutant BCR-ABL clones in chronic myeloid leukemia. <i>Haematologica</i> , 2011 , 96, 347-9	6.6	12
78	Third-line therapy for chronic myeloid leukemia: current status and future directions. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 44	22.4	12
77	Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. <i>BMC Cancer</i> , 2018 , 18, 359	4.8	11
76	Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014 , 14, 231-8	2	11
75	Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. <i>Cancer</i> , 2011 , 117, 982-91	6.4	11
74	Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia. <i>Cancer</i> , 2011 , 117, 3182-6	6.4	11
73	Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays. <i>Cancer Science</i> , 2010 , 101, 2005-10	6.9	11
72	Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 1127-36	5.9	11
71	Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?. <i>Seminars in Hematology</i> , 2010 , 47, 344-53	4	10

70	New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2011 , 52 Suppl 1, 81-91	1.9	10
69	Development and targeted use of nilotinib in chronic myeloid leukemia. <i>Drug Design, Development and Therapy</i> , 2009 , 2, 233-43	4.4	10
68	The clinical challenge of imatinib resistance in chronic myeloid leukemia: emerging strategies with new targeted agents. <i>Targeted Oncology</i> , 2006 , 1, 186-196	5	10
67	Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2020 , 95, 1288-1295	7.1	10
66	TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. <i>Cancer</i> , 2017 , 123, 3717-3724	6.4	9
65	Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001. <i>International Journal of Hematology</i> , 2009 , 90, 58-63	2.3	9
64	Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy?. <i>Current Oncology Reports</i> , 2009 , 11, 337-45	6.3	9
63	Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones. <i>Leukemia Research</i> , 2008 , 32, 1313-6	2.7	9
62	Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside. <i>Cancer</i> , 2003 , 97, 3010-6	6.4	9
61	Chronic myeloid leukemia: sequencing of TKI therapies. <i>Hematology American Society of Hematology Education Program</i> , 2016 , 2016, 164-169	3.1	9
60	Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents. <i>American Journal of Hematology</i> , 2017 , 92, 351-358	7.1	8
59	Dasatinib for the treatment of Philadelphia chromosome-positive leukemias. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 2381-95	4	8
58	Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011 , 11 Suppl 1, S101-10	2	8
57	Acute myeloid leukemia: advancing clinical trials and promising therapeutics. <i>Expert Review of Hematology</i> , 2016 , 9, 433-45	2.8	7
56	Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 1977-86	4	7
55	Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects. <i>Blood</i> , 2010 , 115, 5428-9	2.2	7
54	New agents in the treatment of acute lymphocytic leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2002 , 15, 771-90	4.2	7
53	Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, e871-e882	2	6

52	Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013 , 13, 592-6	2	6
51	Dasatinib for the treatment of chronic myeloid leukemia. <i>Expert Review of Hematology</i> , 2011 , 4, 253-60	2.8	6
50	How to manage CML patients with comorbidities. <i>Blood</i> , 2020 , 136, 2507-2512	2.2	6
49	Chronic myeloid leukaemia. <i>Lancet, The</i> , 2021 , 398, 1914-1926	4.0	6
48	Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1010-6	1.9	5
47	Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment. <i>Cancer Journal (Sudbury, Mass.)</i> , 2007 , 13, 357-65	2.2	5
46	The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis. <i>Haematologica</i> , 2021 , 106, 2853-2858	6.6	5
45	Treatment patterns and deep molecular response in chronic phase - chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study. <i>Leukemia and Lymphoma</i> , 2020 , 61, 98-107	1.9	5
44	CML: the good, the better, and the difficult choices. <i>Blood</i> , 2012 , 120, 3866-7	2.2	4
43	Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 3065-72	4	4
42	Therapeutic options for patients with clonal and idiopathic hypereosinophilia. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 1039-50	5.9	4
41	Pleural Effusion in Patients (pts) with Chronic Myelogenous Leukemia (CML) Treated with Dasatinib after Imatinib Failure.. <i>Blood</i> , 2006 , 108, 2164-2164	2.2	4
40	How to manage CML patients with comorbidities. <i>Hematology American Society of Hematology Education Program</i> , 2020 , 2020, 237-242	3.1	3
39	Molecular resistance: an early indicator for treatment change?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012 , 12, 79-87	2	3
38	Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012 , 12, 197-200	2	3
37	Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2009 , 84, 256-7	7.1	3
36	Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2811-2820	1.9	3
35	Review of New-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. <i>Current Oncology Reports</i> , 2021 , 23, 91	6.3	3

34	Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy. <i>Leukemia and Lymphoma</i> , 2019 , 60, 3172-3180	1.9	2
33	Molecular Biology and Cytogenetics of Chronic Myeloid Leukemia 2018 , 29-47		2
32	Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013 , 13 Suppl 2, S289-94	2	2
31	Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges. <i>Clinical Lymphoma and Myeloma</i> , 2007 , 7 Suppl 2, S51-7		2
30	Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia. <i>Current Hematologic Malignancy Reports</i> , 2007 , 2, 83-8	4.4	2
29	The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia 2020 , 8,		2
28	Chronic Myeloid Leukemia 2016 , 1-11		2
27	Chronic myeloid leukemia 2019 , 71-86		1
26	Molecular Biology and Cytogenetics of Chronic Myeloid Leukemia 2013 , 29-44		1
25	Optimizing first-line therapy for patients with chronic myeloid leukemia. <i>Seminars in Hematology</i> , 2009 , 46, S5-10	4	1
24	New approaches to the management of Philadelphia-chromosome-positive acute lymphocytic leukemia. <i>Current Hematologic Malignancy Reports</i> , 2007 , 2, 183-9	4.4	1
23	Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase. <i>Current Opinion in Internal Medicine</i> , 2007 , 14, 138-44		1
22	Chronic Myeloid Leukemia 2014 , 1944-1957.e2		1
21	The significance of major and stable molecular responses in chronic myeloid leukemia in the tyrosine kinase inhibitor era. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2011 , 33, 455-60		1
20	ASH 2009 meeting report—Top 10 clinically oriented abstracts in acute leukemia. <i>American Journal of Hematology</i> , 2010 , 85, 277-280	7.1	0
19	Targeted Therapies in Chronic Myeloid Leukemia 2015 , 111-120		
18	Chronic myeloid leukemia: the race is yet to be won. <i>Cmaj</i> , 2012 , 184, 857-8	3.5	
17	Phase II trials of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. <i>Expert Opinion on Orphan Drugs</i> , 2013 , 1, 607-623	1.1	

- 16 Novel treatment options for acute myelocytic leukemia. *Clinical Investigation*, **2013**, 3, 979-990
- 15 Scrotal Edema Associated with the Use of Dasatinib in Patients with Chronic Myeloid Leukemia. *Clinical Leukemia*, **2007**, 1, 357-358
- 14 Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate. *Leukemia Research*, **2008**, 32, 1468-71 2.7
- 13 The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia. *Leukemia and Lymphoma*, **2007**, 48, 802-4 1.9
- 12 Dasatinib: A Dual ABL and SRC Inhibitor **2006**, 59-68
- 11 Investigational agents in myeloid disorders. *Advances in Pharmacology*, **2004**, 51, 59-97 5.7
- 10 Comments on the Hammersmith policy. *Seminars in Hematology*, **2003**, 40, 105-106 4
- 9 Targeted Therapy in Myelodysplastic Syndrome **2008**, 237-260
- 8 Targeted Therapy in Chronic Myeloid Leukemia **2008**, 87-99
- 7 New Therapies for Chronic Myeloid Leukemia **2007**, 165-184
- 6 Biology of Chronic and Acute Myeloid Leukemia **2008**, 371-383
- 5 Chronic Myeloid Leukemia: Pathophysiology and Therapeutics **2010**, 139-153
- 4 Standard Management of Patients with Chronic Myeloid Leukemia 71-85
- 3 New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid Leukemia. *Applied Immunohistochemistry and Molecular Morphology*, **2019**, 27, 33-39 1.9
- 2 Chronic Myeloid Leukemia **2020**, 1836-1849.e2
- 1 CML Therapy: A Focus on Second- and Third-Generation Tyrosine Kinase Inhibitors. *Hematologic Malignancies*, **2021**, 61-76 0